Top in hem/onc: Optimism in oncology, active surveillance for low-risk prostate cancer

In a recent article, Nicholas J. Petrelli, MD, FACS, associate editor of surgical oncology for HemOnc Today, reflected on the power of optimism and progress in cancer care that has increased survival and quality of life among patients.

It was the top story in hematology/oncology last week.

Another top story examined the proportion of men with low-risk prostate cancer who switched from active surveillance to active treatment. Researchers reported that 50.8% of men discontinued active surveillance primarily due to tumor progression after a median follow-up of 48 months.

Read these and more top stories in hematology/oncology below:

A lesson from the Iron Man

The progress made over the past decade in immunotherapy, targeted therapy, gene editing and gene profiling has led to increased survival and better quality of life for many patients with cancer. Read more.

Many men with low-risk prostate cancer switch from active surveillance to active treatment

Use of active surveillance for low-risk prostate cancer increased significantly over time, but a relatively high rate of men switched to definitive treatment within 5 years, according to a population-based study in The Journal of Urology. Read more.

Setting boundaries, focusing on purpose can promote resilience among women in medicine

According to Laurie K. Baedke, MHA, FACHE, FACMPE, saying “no” on its own stands as a complete sentence. Read more.

Oncologist outlines how to navigate through toxic work environments

Pamela L. Kunz, MD, spoke at the Women in Medicine Summit meeting about navigating a toxic work environment, sharing a mix of her personal journey, concrete data on harassment and steps toward a solution. Read more.

Primer for physicians: Economic ramifications of owning a vacation home

Work hard, play hard. Physicians, young and old, enjoy time off and vacationing. Read more.